자궁경부암 예방 백신의 효과와 공중보건학적 의의 = Efficacy of Human Papillomavirus Vaccines as an Anticancer Vaccine

다국어 초록 (Multilingual Abstract)

Objectives: Aim of study is to review efficacies of two human papillomavirus vaccines in different study populations and examine importance of HPV vaccine as a routine vaccine.
Methods: Four phase-3 efficacy studies of two HPV vaccines were reviewed. Magnitude of efficacies were compared among different study populations.
Results: Recently, two kinds of papillomavirus (HPV) vaccines were developed. "Cervarix" is a bivalent vaccine which contained L1 protein of HPV 16 and HPV 18, and "Gardasil" is a quadrivalent vaccine which contained L1 protein of HPV 6 and HPV 11 in addition. Efficacy study showed that both vaccine are highly effective to prevent cervical, vaginal and vulvar precancerous lesion in the population who are naive to HPV infection. Quadrivalent vaccine also showed high efficacy to prevent genital warts. Efficacy of the vaccine decreased in the general population who included both HPV-naive and HPV-infected peoples. Both vaccines showed high immune responses for 5 years after vaccination.
Conclusions: From the point of public health, HPV vaccine is an important vaccine for young adolescents who have not begun sexual activity. However, development of guidelines for HPV vaccination for each country will be dependent on cost effectiveness of HPV vaccines of each population.

참고문헌 (Reference)

1 Harper DM, "Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial" 367 (367): 1247-1255, 2006

2 Koutsky LA (et al), "Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions" 356 (356): 1915-1927, 2007

3 CDC, "Quadrivalent Human Papillomavirus Vaccine" MMWR 26 : 1-24, 2007

4 Olsson SE, "Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine" 25 (25): 4931-4399, 2007

5 Villa LL, "Immunologic responses following dministration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18" 24 (24): 5571-5583, 2006

6 Stanley M, "Immune responses to human papillomavirus" 24 (24): S16-22, 2006

7 Villa LL, "High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up" 95 (95): 1459-1466, 2006

8 Garland SM, "Females United to Unilaterally Reduce Endo/ Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases" 356 (356): 1928-1943, 2007

9 Munoz N, "Epidemiologic classification of human papillomavirus types associated with cervical cancer" 348 (348): 518-527,

10 Joura EA, "Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials" 369 (369): 1693-1702, 2007

11 Paavonen J, "Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial" 369 (369): 2161-2170, 2007

12 Pagliusi, S. R, "Efficacy and other milestones for human papillomavirus vaccine introduction" 23 (23): 569-578,

13 Ault KA, "Effect of prophylactic human papillomavirus L1 virus-like- particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials" 369 (369): 1861-1868, 2007

14 Burchell AN, "Chapter 6: Epidemiology and transmission dynamics of genital HPV infection" 24 (24): S52-61,

15 Koutsky LA, "Chapter 13: Current findings from prophylactic HPV vaccine trials" 24 (24): S114-121, 2006